JP2000509724A - ヌクレオチド又はオリゴヌクレオチドホスホロアミダイトの合成方法 - Google Patents
ヌクレオチド又はオリゴヌクレオチドホスホロアミダイトの合成方法Info
- Publication number
- JP2000509724A JP2000509724A JP10530084A JP53008498A JP2000509724A JP 2000509724 A JP2000509724 A JP 2000509724A JP 10530084 A JP10530084 A JP 10530084A JP 53008498 A JP53008498 A JP 53008498A JP 2000509724 A JP2000509724 A JP 2000509724A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phosphoramidite
- mol
- formula
- dimethoxytrityl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 63
- 150000008300 phosphoramidites Chemical class 0.000 title claims abstract description 29
- 108091034117 Oligonucleotide Proteins 0.000 title description 36
- 239000002773 nucleotide Substances 0.000 title description 6
- 125000003729 nucleotide group Chemical group 0.000 title description 6
- 230000002194 synthesizing effect Effects 0.000 title description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 48
- -1 phosphoryl protecting group Chemical group 0.000 claims description 44
- 150000001875 compounds Chemical class 0.000 claims description 17
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 14
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 12
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 9
- 150000004713 phosphodiesters Chemical class 0.000 claims description 8
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 229930024421 Adenine Natural products 0.000 claims description 7
- 229960000643 adenine Drugs 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 229940104302 cytosine Drugs 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims description 6
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 6
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 6
- 229940113082 thymine Drugs 0.000 claims description 6
- OMIKXSTXQGXCJT-UHFFFAOYSA-N NP(O)O.NP(O)O.NP(O)O.N.N Chemical compound NP(O)O.NP(O)O.NP(O)O.N.N OMIKXSTXQGXCJT-UHFFFAOYSA-N 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 229940035893 uracil Drugs 0.000 claims description 4
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 229920000570 polyether Polymers 0.000 claims description 3
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 10
- 238000003786 synthesis reaction Methods 0.000 abstract description 10
- 239000002699 waste material Substances 0.000 abstract description 6
- 150000001412 amines Chemical class 0.000 abstract description 2
- IMQJPKVZEGEERX-UHFFFAOYSA-N BrC1=C(C(=C(O[PH2](Cl)Cl)C=C1)Br)Br Chemical compound BrC1=C(C(=C(O[PH2](Cl)Cl)C=C1)Br)Br IMQJPKVZEGEERX-UHFFFAOYSA-N 0.000 abstract 1
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 52
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 39
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 39
- 229910052786 argon Inorganic materials 0.000 description 26
- 239000000047 product Substances 0.000 description 19
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 18
- ACXYOQYLAANNIF-UHFFFAOYSA-N dichloro-tris(2,4,6-tribromophenoxy)-$l^{5}-phosphane Chemical compound BrC=1C=C(Br)C=C(Br)C=1OP(Cl)(OC=1C(=CC(Br)=CC=1Br)Br)(Cl)OC1=C(Br)C=C(Br)C=C1Br ACXYOQYLAANNIF-UHFFFAOYSA-N 0.000 description 16
- 230000000692 anti-sense effect Effects 0.000 description 15
- 239000002777 nucleoside Substances 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 239000012300 argon atmosphere Substances 0.000 description 13
- 239000012043 crude product Substances 0.000 description 13
- 229940043279 diisopropylamine Drugs 0.000 description 13
- 238000003818 flash chromatography Methods 0.000 description 13
- 239000007789 gas Substances 0.000 description 13
- 239000011521 glass Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- 125000006239 protecting group Chemical group 0.000 description 12
- 150000003833 nucleoside derivatives Chemical class 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 238000002515 oligonucleotide synthesis Methods 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 235000000346 sugar Nutrition 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 150000003230 pyrimidines Chemical class 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 150000008163 sugars Chemical class 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- WPPONCHFOIIFIJ-UHFFFAOYSA-N N1N=NN=[C-]1 Chemical compound N1N=NN=[C-]1 WPPONCHFOIIFIJ-UHFFFAOYSA-N 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009510 drug design Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 150000003335 secondary amines Chemical class 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
- CPDFBOPDCAFMMX-UHFFFAOYSA-N 2-benzhydrylsilylethylphosphonic acid Chemical compound C1=CC=C(C=C1)C(C2=CC=CC=C2)[SiH2]CCP(=O)(O)O CPDFBOPDCAFMMX-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- LOJNBPNACKZWAI-UHFFFAOYSA-N 3-nitro-1h-pyrrole Chemical group [O-][N+](=O)C=1C=CNC=1 LOJNBPNACKZWAI-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 125000000824 D-ribofuranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@]1([H])O[H] 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- XVZQWVIZVVBJFF-IJMFZQBRSA-N [(2R,3R,4R,5R)-5-(6-amino-6-benzoyl-8H-purin-9-yl)-2-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-(2-benzhydrylsilylethyl)phosphinic acid Chemical compound C1(=CC=CC=C1)C(C1=CC=CC=C1)[SiH2]CCP(O)(=O)O[C@H]1[C@H]([C@@H](O[C@@H]1COC(C1=CC=C(C=C1)OC)(C1=CC=C(C=C1)OC)C1=CC=CC=C1)N1CN=C2C(N)(N=CN=C12)C(C1=CC=CC=C1)=O)OCCOC XVZQWVIZVVBJFF-IJMFZQBRSA-N 0.000 description 1
- CKGPFIXZKGCXSV-IRKLRGACSA-N [(2R,3S,5R)-5-(6-amino-6-benzoyl-8H-purin-9-yl)-2-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]oxolan-3-yl]oxy-(2-benzhydrylsilylethyl)phosphinic acid Chemical compound C1(=CC=CC=C1)C(C1=CC=CC=C1)[SiH2]CCP(O)(=O)O[C@H]1C[C@@H](O[C@@H]1COC(C1=CC=C(C=C1)OC)(C1=CC=C(C=C1)OC)C1=CC=CC=C1)N1CN=C2C(N)(N=CN=C12)C(C1=CC=CC=C1)=O CKGPFIXZKGCXSV-IRKLRGACSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000007040 multi-step synthesis reaction Methods 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000001293 nucleolytic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 239000002719 pyrimidine nucleotide Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- IIRLDRQVSDQJMN-UHFFFAOYSA-N tribromo-chloro-phenoxy-$l^{5}-phosphane Chemical compound ClP(Br)(Br)(Br)OC1=CC=CC=C1 IIRLDRQVSDQJMN-UHFFFAOYSA-N 0.000 description 1
- QVHFZPCRYUJZDR-UHFFFAOYSA-N trichloro-bis(2,4,6-tribromophenoxy)-$l^{5}-phosphane Chemical compound BrC=1C=C(Br)C=C(Br)C=1OP(Cl)(Cl)(Cl)OC1=C(Br)C=C(Br)C=C1Br QVHFZPCRYUJZDR-UHFFFAOYSA-N 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
- 229940102001 zinc bromide Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ホスホロアミダイトを製造する方法であって: 式: 〔式中: Zは、ヌクレオシド間連結であり; R1は、ヒドロキシル保護基であり; R2は、H、OH、O−アルキル、O−アルキルアミノ、O−アルキルアルコ キシ、式(O−アルキル)mのポリエーテル(式中、mは1〜約10である)、 又は保護されたヒドロキシル基であり; R3は、ホスホリル保護基であり; Bは、ヌクレオベースであり;そして nは、0〜約100である。〕 の化合物を式:〔式中: X1は、Br又はClであり; X2及びX3は、独立に、H、Br又はClであり; x及びyは、各々独立に、2又は3であり、そしてxとyの合計が5である。 〕 の化合物と反応させる工程;及び 該反応の生成物を式HN(Q)2の化合物と接触させて、式: 〔式中、各々のQは、独立に1〜15の炭素を有するアルキル、6〜14の炭素 を有するアリールであるか、又は該ホスホロアミダイト窒素と2〜10の炭素を 有する複素環を形成することができる。〕 のホスホロアミダイトを生成させる工程を含んでなる方法。 2.Qがイソプロピルである、請求項1記載の方法。 3.R2がHである、請求項1記載の方法。 4.R2が保護されたヒドロキシル基である、請求項1記載の方法。 5.R2がO−アルキル又はO−アルキルアルコキシである、請求項1記載 の方法。 6.R2がO−アルキルアルコキシである、請求項1記載の方法。 7.R2が2−メトキシエトキシである、請求項1記載の方法。 8.R3が、シアノエチル、4−シアノ−2−ブテニル、又はジフェニルメ チルシリルエチルである、請求項1記載の方法。 9.xが2でありyが3である、請求項1記載の方法。 10.xが3でありyが2である、請求項1記載の方法。 11.反応が溶媒の存在下で行われる、請求項1記載の方法。 12.溶媒がアセトニトリルである、請求項11記載の方法。 13.ヌクレオベースが、アデニン、グアニン、シトシン、チミン、ウラシル 、5−メチルシトシン又はそれらの保護された誘導体である、請求項1記載の方 法。 14.Zが、ホスホジエステル連結、ホスホロチオエート連結、ホスホロジチ オエート連結、又はホスホネート連結である、請求項1記載の方法。 15.Zがホスホジエステル連結又はホスホロチオエート連結である、請求項 14記載の方法。 16.R3がシアノエチルである、請求項1記載の方法。 17.R3が4−シアノ−2−ブテニルである、請求項1記載の方法。 18.X1、X2及びX3がフェニル環の2、4及び6位に位置しているBrで ある、請求項1記載の方法。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/775,019 | 1996-12-27 | ||
| US08/775,019 US5955600A (en) | 1996-12-27 | 1996-12-27 | Method for the synthesis of nucleotide or oligonucleotide phosphoramidites |
| PCT/US1997/023269 WO1998029429A1 (en) | 1996-12-27 | 1997-12-16 | Method for the synthesis of nucleotide or oligonucleotide phosphoramidites |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000509724A true JP2000509724A (ja) | 2000-08-02 |
| JP3675847B2 JP3675847B2 (ja) | 2005-07-27 |
Family
ID=25103076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53008498A Expired - Fee Related JP3675847B2 (ja) | 1996-12-27 | 1997-12-16 | ヌクレオチド又はオリゴヌクレオチドホスホロアミダイトの合成方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5955600A (ja) |
| EP (1) | EP0948514B1 (ja) |
| JP (1) | JP3675847B2 (ja) |
| AT (1) | ATE294186T1 (ja) |
| AU (1) | AU5529398A (ja) |
| DE (1) | DE69733150T2 (ja) |
| WO (1) | WO1998029429A1 (ja) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004533488A (ja) * | 2001-07-03 | 2004-11-04 | アベシア・バイオテクノロジー・インコーポレーテッド | オリゴヌクレオチド合成用のアクチベーター |
| JP2006512411A (ja) * | 2002-12-18 | 2006-04-13 | アベシア・リミテッド | オリゴヌクレオチドの調製方法 |
| JP5554881B2 (ja) * | 2011-08-25 | 2014-07-23 | 株式会社ボナック | 配糖体化合物、チオエーテルの製造方法、エーテル、エーテルの製造方法、配糖体化合物の製造方法、核酸の製造方法 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5827321A (en) * | 1997-02-07 | 1998-10-27 | Cornerstone Devices, Inc. | Non-Foreshortening intraluminal prosthesis |
| US20040267350A1 (en) * | 2002-10-30 | 2004-12-30 | Roubin Gary S. | Non-foreshortening intraluminal prosthesis |
| JPH1180185A (ja) * | 1997-09-05 | 1999-03-26 | Res Dev Corp Of Japan | オリゴヌクレオチドの化学合成法 |
| US6441150B1 (en) * | 1997-12-16 | 2002-08-27 | Isis Pharmaceuticals, Inc. | Compounds for the Synthesis of Nucleotide or oligonucleotide phosphoramidites |
| US6020475A (en) * | 1998-02-10 | 2000-02-01 | Isis Pharmeuticals, Inc. | Process for the synthesis of oligomeric compounds |
| US6207819B1 (en) * | 1999-02-12 | 2001-03-27 | Isis Pharmaceuticals, Inc. | Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds |
| US7030230B2 (en) | 2002-10-25 | 2006-04-18 | Isis Pharmaceuticals, Inc. | Process of purifying phosphoramidites |
| ES2403937T3 (es) | 2003-11-13 | 2013-05-22 | Isis Pharmaceuticals, Inc. | Derivados de 5,6-dihidroxi-isoindol como conectores para la síntesis de oligómeros en fase sólida |
| WO2006023880A2 (en) * | 2004-08-23 | 2006-03-02 | Isis Pharmaceuticals, Inc. | Compounds and methods for the characterization of oligonucleotides |
| US20060105348A1 (en) * | 2004-11-15 | 2006-05-18 | Lee Jun E | Compositions and methods for the detection and discrimination of nucleic acids |
| US20060275792A1 (en) * | 2004-11-15 | 2006-12-07 | Lee Jun E | Enhancement of nucleic acid amplification using double-stranded DNA binding proteins |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3687808A (en) * | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| US4500707A (en) * | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US4458066A (en) * | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4668777A (en) * | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4415732A (en) * | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
| US5212295A (en) * | 1990-01-11 | 1993-05-18 | Isis Pharmaceuticals | Monomers for preparation of oligonucleotides having chiral phosphorus linkages |
| US5489677A (en) * | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
-
1996
- 1996-12-27 US US08/775,019 patent/US5955600A/en not_active Expired - Fee Related
-
1997
- 1997-12-16 AT AT97951728T patent/ATE294186T1/de not_active IP Right Cessation
- 1997-12-16 AU AU55293/98A patent/AU5529398A/en not_active Abandoned
- 1997-12-16 WO PCT/US1997/023269 patent/WO1998029429A1/en not_active Ceased
- 1997-12-16 JP JP53008498A patent/JP3675847B2/ja not_active Expired - Fee Related
- 1997-12-16 EP EP97951728A patent/EP0948514B1/en not_active Expired - Lifetime
- 1997-12-16 DE DE69733150T patent/DE69733150T2/de not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004533488A (ja) * | 2001-07-03 | 2004-11-04 | アベシア・バイオテクノロジー・インコーポレーテッド | オリゴヌクレオチド合成用のアクチベーター |
| JP2006512411A (ja) * | 2002-12-18 | 2006-04-13 | アベシア・リミテッド | オリゴヌクレオチドの調製方法 |
| JP5554881B2 (ja) * | 2011-08-25 | 2014-07-23 | 株式会社ボナック | 配糖体化合物、チオエーテルの製造方法、エーテル、エーテルの製造方法、配糖体化合物の製造方法、核酸の製造方法 |
| US9481702B2 (en) | 2011-08-25 | 2016-11-01 | Bonac Corporation | Glycoside compound, method for producing thioether, ether, method for producing ether, method for producing glycoside compound, method for producing nucleic acid |
| US9988415B2 (en) | 2011-08-25 | 2018-06-05 | Bonac Corporation | Glycoside compound, method for producing thioether, ether, method for producing ether, method for producing glycoside compound, method for producing nucleic acid |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998029429A1 (en) | 1998-07-09 |
| EP0948514A4 (en) | 2001-10-24 |
| DE69733150T2 (de) | 2006-03-02 |
| AU5529398A (en) | 1998-07-31 |
| EP0948514A1 (en) | 1999-10-13 |
| ATE294186T1 (de) | 2005-05-15 |
| JP3675847B2 (ja) | 2005-07-27 |
| DE69733150D1 (de) | 2005-06-02 |
| US5955600A (en) | 1999-09-21 |
| EP0948514B1 (en) | 2005-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6191266B1 (en) | Sugar modified nucleosides | |
| JP2004500330A (ja) | グアニジニウム官能化オリゴマーとその製造法 | |
| JP2002517404A (ja) | オリゴヌクレオチド合成のためのアクチベーター | |
| EP1314734A1 (en) | Novel nucleoside analogs and oligonucleotide derivatives containing these analogs | |
| JPH07300493A (ja) | 2′−エーテル基を有する、ヌクレオシド及びオリゴヌクレオチド | |
| WO1997030064A1 (en) | Hexitol containing oligonucleotides and their use in antisense strategies | |
| JP3675847B2 (ja) | ヌクレオチド又はオリゴヌクレオチドホスホロアミダイトの合成方法 | |
| Hunziker et al. | Nucleic acid analogues: synthesis and properties | |
| JP2000512630A (ja) | 2’―置換ヌクレオシドおよびオリゴヌクレオチド誘導体 | |
| WO1998049179A2 (en) | A process for the synthesis of modified p-chiral nucleotide analogues | |
| KR100458979B1 (ko) | 포스포로티오에이트 올리고뉴클레오티드의 합성 방법 | |
| US6858722B2 (en) | Oligomer phosphoramidite compositions and processes for synthesizing the same | |
| US6743902B1 (en) | Sugar modified nucleosides | |
| US6458941B1 (en) | Compounds for the synthesis of nucleotide or oligonucleotide phosphoramidites | |
| US7166718B2 (en) | Calix[4]arene-nucleoside and calix[4]oligonucleotide hybrids | |
| WO1995031470A2 (en) | Antisense inhibitors of gene expression | |
| US6103891A (en) | Method for the synthesis of nucleotide or oligonucleotide phosphoramidites | |
| JPH069682A (ja) | レトロウイルス感染用治療薬としてのポリヌクレオチドホスホロジチオエート | |
| JP2005514462A6 (ja) | 新規カリックス[4]アレーン−ヌクレオシドおよびカリックス[4]アレーン−オリゴヌクレオチドハイブリッド | |
| JPH0995495A (ja) | アンチセンスオリゴヌクレオチド、並びに、その製造用中間体であるヌクレオシド及びその合成方法並びにオリゴヌクレオチド合成ユニット及びその合成方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040210 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041102 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050202 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050329 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050427 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090513 Year of fee payment: 4 |
|
| LAPS | Cancellation because of no payment of annual fees | ||
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |